system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Adult, Analysis of Variance, Antibodies, Monoclonal, Antirheumatic Agents, Biomarkers, C-Reactive Protein, Cytokines, Drug Monitoring, Female, Follow-Up Studies, Humans, Infliximab, Male, Middle Aged, Patient Selection, Prognosis, Spondylitis, Ankylosing, Treatment Outcome, Tumor Necrosis Factor-alpha.
user
Does cytokine correlate of clinical response patterns to infliximab treatment of ankylosing spondylitis? Context: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p<0.01 and p<0.006, respectively). The two groups had similar baseline cytokine levels, apart from TNFalpha. Baseline CRP levels did not correlate significantly with baseline cytokine levels in responders, but a strong correlation was noted between baseline CRP and IL1, IFNgamma, and IL10 in non-responders. Apart from an early rise in TGFbeta and a decrease in IL10 in responders after the first infusion, sequential cytokine analysis for the first six months of treatment was not related to clinical disease activity measures.
assistant
Although sequential cytokine analysis does not appear to be informative, baseline CRP and TNFalpha levels are useful markers of clinical response patterns in patients with AS treated with infliximab. Final Decision: yes